DexCom (DXCM)
(Delayed Data from NSDQ)
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$65.68 USD
-1.42 (-2.12%)
Updated Oct 3, 2024 04:00 PM ET
After-Market: $65.69 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Here's Why You Should Buy Integer Holdings (ITGR) Stock Now
by Zacks Equity Research
Integer Holdings' (ITGR) bullish guidance paints a bright picture. Moreover, its solid focus on portfolio management is likely to provide the company with a competitive edge in the MedTech space.
DexCom (DXCM) Beats Q3 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q3 results.
DexCom (DXCM) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
DexCom (DXCM) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
DexCom (DXCM) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 241.67% and 10.17%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
DexCom Launches CLARITY Mobile App, Strengthens CGM Profile
by Zacks Equity Research
DexCom (DXCM) benefits from the diabetes care space as it adopts cloud-based services for Continuous Glucose Monitoring.
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Masimo, Medtronic, Garmin and DexCom
Wearable Medical Device Boom Puts These 3 Stocks in Focus
by Nabaparna Bhattacharya
Americans depend on wearable medical devices for fitness tracking, blood pressure maintenance, self-glucose monitoring and more. Here, we discuss major companies that are raking in huge profits.
US Diabetes Market Gaining Momentum: 3 Stocks in Focus
by Sreyoshi Mukherjee
A rising geriatric population and lifestyle disorders are expanding the U.S. diabetic population.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
DexCom (DXCM) Up 15.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should First Trust Mid Cap Growth AlphaDEX Fund (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Here's Why You Should Hold On to DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is expected to benefit from lucrative prospects in the diabetes market. However, the company's margins were under pressure in the last reported quarter.
DexCom (DXCM) Beats Q2 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from the Sensor, Transmitter and Receiver segments drives DexCom's (DXCM) Q2 results.
DexCom (DXCM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
DexCom (DXCM) delivered earnings and revenue surprises of 50.00% and 18.38%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can PBM Unit Boost Express Scripts' (ESRX) Q2 Earnings?
by Zacks Equity Research
Strong performance by the PBM unit is likely to drive Express Scripts' (ESRX) top line in Q2. Home-delivery pharmacy care, specialty pharmacy care and drug data analysis services buoy optimism.
Will Global Industrial Unit Boost Ecolab's (ECL) Q2 Earnings?
by Zacks Equity Research
Solid performance in the Global Industrial segment is likely to drive Ecolab's (ECL) Q2 results. However, the company faces pricing pressure in the Energy segment.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q2 Earnings?
by Zacks Equity Research
Strong performance in the Diagnostics Segment is likely to drive PerkinElmer's (PKI) Q2 results. The segment fortifies the company's market position in terms of exclusiveness of services.
Merit Medical (MMSI) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
Merit Medical's (MMSI) acquisition-driven strategy to boost growth by expanding existing product offerings across all business segments in Q2.
What's in Store for AngioDynamics (ANGO) in Q4 Earnings?
by Zacks Equity Research
AngioDynamics' (ANGO) expanding product pipeline, international market expansion and cost-saving initiatives to provide growth opportunities in Q4.
DexCom (DXCM) Up 17.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
DexCom (DXCM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Sweta Killa
Smart Beta ETF report for XHE
DexCom (DXCM) Meets Q1 Earnings Estimates, Raises '18 View
by Zacks Equity Research
Solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues drive DexCom's (DXCM) Q1 results.
Is SPDR S&P Health Care Equipment ETF (XHE) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
DexCom (DXCM) Gets FDA Approval for G6 CGM Monitoring System
by Zacks Equity Research
DexCom (DXCM) is a leading player in the global CGM markets.
DexCom (DXCM) Surpasses Earnings & Revenue Estimates in Q4
by Zacks Equity Research
DexCom (DXCM) rides high on strength in all segments in Q4.